Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Core Insights - Aclaris Therapeutics is entering a transformative multi-year period with significant milestones expected in 2025 and 2026, focusing on immuno-inflammatory diseases [2] - The company has extended its expected cash runway through the first half of 2028, allowing for continued execution of its clinical programs [2][11] - Aclaris has received positive Phase 2 results from its Chinese partner CTTQ, indicating enhanced potency of its investigational drug bosakitug (ATI-045) [3][5] - The U.S. FDA has cleared the Investigational New Drug (IND) application for ATI-052, a bispecific antibody, paving the way for its clinical trials [7] Pipeline Developments - Bosakitug (ATI-045) is an investigational anti-TSLP monoclonal antibody, with plans to initiate a placebo-controlled Phase 2 trial in atopic dermatitis (AD) in Q2 2025 [5] - ATI-2138, an oral ITK/JAK3 inhibitor, is also set for new clinical trials, with top-line results from a Phase 2a trial in AD expected in June 2025 [6] - Aclaris intends to seek partnerships for the global development of bosakitug in respiratory indications, while maintaining focus on dermatological applications [5] Financial Performance - For Q1 2025, Aclaris reported a net loss of $15.1 million, an improvement from a loss of$16.9 million in Q1 2024 [12] - Total revenue for Q1 2025 was $1.5 million, down from$2.4 million in the same period last year, primarily due to a decrease in royalty payments [12] - Research and development expenses increased to $11.6 million in Q1 2025, driven by costs associated with the bosakitug program [13] Corporate Updates - Aclaris has appointed Dr. Jesse W. Hall as Chief Medical Officer, bringing extensive experience in drug development [10] - The company is exploring additional non-dilutive financing opportunities following the lifting of an injunction against Sun Pharmaceuticals, which may provide a financial asset for monetization [11]